Oppenheimer & Co’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$45.5M Buy
186,168
+8,269
+5% +$1.93M 0.55% 30
2025
Q4
$36.8M Sell
177,899
-5,452
-3% -$1.08M 0.52% 28
2025
Q3
$34M Buy
183,351
+1,273
+0.7% +$218K 0.41% 33
2025
Q2
$27.8M Buy
182,078
+4,310
+2% +$662K 0.37% 39
2025
Q1
$29.5M Sell
177,768
-3,745
-2% -$586K 0.45% 34
2024
Q4
$26.3M Buy
181,513
+1,838
+1% +$285K 0.39% 40
2024
Q3
$29.1M Buy
179,675
+87
+0% +$13.9K 0.44% 34
2024
Q2
$26.2M Buy
179,588
+470
+0.3% +$69.9K 0.42% 37
2024
Q1
$28.3M Sell
179,118
-11,886
-6% -$1.89M 0.47% 29
2023
Q4
$29.9M Sell
191,004
-7,515
-4% -$1.15M 0.55% 22
2023
Q3
$30.9M Sell
198,519
-32,508
-14% -$5.36M 0.64% 17
2023
Q2
$38.2M Sell
231,027
-11,705
-5% -$1.89M 0.77% 15
2023
Q1
$37.6M Buy
242,732
+5,936
+3% +$959K 0.8% 13
2022
Q4
$41.8M Sell
236,796
-63,589
-21% -$11M 0.95% 9
2022
Q3
$49.1M Buy
300,385
+4,466
+2% +$756K 1.15% 5
2022
Q2
$52.5M Sell
295,919
-1,025
-0.3% -$183K 1.13% 6
2022
Q1
$52.6M Buy
296,944
+8,880
+3% +$1.51M 0.95% 7
2021
Q4
$49.3M Sell
288,064
-3,909
-1% -$640K 0.86% 12
2021
Q3
$47.2M Sell
291,973
-902
-0.3% -$154K 0.88% 10
2021
Q2
$48.2M Buy
292,875
+2,895
+1% +$479K 0.86% 11
2021
Q1
$47.7M Sell
289,980
-2,395
-0.8% -$388K 0.95% 8
2020
Q4
$46M Buy
292,375
+13,598
+5% +$2.01M 0.97% 8
2020
Q3
$41.5M Sell
278,777
-9,367
-3% -$1.39M 1.04% 8
2020
Q2
$40.5M Buy
288,144
+9,778
+4% +$1.42M 1.05% 7
2020
Q1
$36.5M Buy
278,366
+43,027
+18% +$6.1M 1.11% 9
2019
Q4
$34.3M Buy
235,339
+17,384
+8% +$2.36M 0.85% 13
2019
Q3
$28.2M Sell
217,955
-2,984
-1% -$393K 0.77% 16
2019
Q2
$30.8M Sell
220,939
-25,542
-10% -$3.54M 0.84% 17
2019
Q1
$34.5M Buy
246,481
+4,608
+2% +$617K 0.92% 12
2018
Q4
$31.2M Sell
241,873
-8,214
-3% -$1.15M 0.98% 12
2018
Q3
$34.6M Buy
250,087
+8,611
+4% +$1.14M 0.88% 10
2018
Q2
$29.3M Sell
241,476
-1,990
-0.8% -$248K 0.8% 13
2018
Q1
$31.2M Sell
243,466
-4,005
-2% -$541K 0.8% 13
2017
Q4
$34.6M Buy
247,471
+4,944
+2% +$689K 0.89% 11
2017
Q3
$31.5M Sell
242,527
-8,234
-3% -$1.09M 0.84% 12
2017
Q2
$33.2M Buy
250,761
+2,725
+1% +$348K 0.91% 10
2017
Q1
$30.9M Sell
248,036
-27,691
-10% -$3.31M 0.87% 11
2016
Q4
$31.8M Sell
275,727
-2,294
-0.8% -$265K 0.92% 10
2016
Q3
$32.8M Sell
278,021
-7,869
-3% -$955K 0.96% 8
2016
Q2
$34.7M Buy
285,890
+2
+0% +$227 1.03% 8
2016
Q1
$30.9M Sell
285,888
-3,808
-1% -$394K 0.94% 9
2015
Q4
$29.8M Buy
289,696
+6,978
+2% +$702K 0.89% 10
2015
Q3
$26.4M Buy
282,718
+44,826
+19% +$4.34M 0.8% 11
2015
Q2
$23.2M Sell
237,892
-15,537
-6% -$1.56M 0.65% 16
2015
Q1
$25.5M Buy
253,429
+29,887
+13% +$3.04M 0.69% 14
2014
Q4
$23.4M Sell
223,542
-19,210
-8% -$2.02M 0.67% 17
2014
Q3
$25.9M Sell
242,752
-6,651
-3% -$690K 0.77% 10
2014
Q2
$26.1M Sell
249,403
-5,540
-2% -$560K 0.79% 10
2014
Q1
$25M Buy
254,943
+6,543
+3% +$607K 0.75% 15
2013
Q4
$22.8M Sell
248,400
-20,901
-8% -$1.93M 0.73% 15
2013
Q3
$23.3M Buy
269,301
+26,945
+11% +$2.42M 0.82% 8
2013
Q2
$20.8M Buy
+242,356
New +$20.6M 0.8% 11

Other funds holding JNJ

Oppenheimer & Co's JNJ Position: Q1 2026 in Review

Oppenheimer & Co increased its Johnson & Johnson (JNJ) stake by 4.6% in Q1 2026, buying an estimated $1.93M and bringing the position to 186,168 shares worth $45.5M. The position accounts for 0.55% of the portfolio, ranked #30.

Oppenheimer & Co first reported a position in JNJ in Q2 2013 and has held it in 52 quarters since. The position peaked at $52.6M in Q1 2022. 4,618 funds tracked by Wall St. Rank hold JNJ as of Q1 2026.

  • Oppenheimer & Co held 186,168 shares of Johnson & Johnson worth $45.5M as of Q1 2026.
  • Oppenheimer & Co bought 8,269 Johnson & Johnson shares in Q1 2026, an estimated $1.93M.
  • Johnson & Johnson made up 0.55% of Oppenheimer & Co's portfolio in Q1 2026, its #30 holding.
  • Oppenheimer & Co first reported a position in Johnson & Johnson in Q2 2013 and has held it in 52 quarters since.
  • Oppenheimer & Co's Johnson & Johnson position peaked at $52.6M in Q1 2022.
  • 4,618 funds tracked by Wall St. Rank held Johnson & Johnson as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.